Contagious Bovine Pleuropneumonia

Contagious bovine pleuropneumonia (CBPP) is a severe, highly contagious respiratory disease affecting cattle caused by the bacterium Mycoplasma mycoides subspecies mycoides small colony type (MmmSC). This devastating illness represents one of the most economically significant diseases impacting cattle populations worldwide, particularly in sub-Saharan Africa where it remains endemic in many regions. The disease is characterized by severe inflammation of the lungs and pleural membranes, leading to significant respiratory compromise and high mortality rates in affected herds. CBPP has been recognized for centuries and was once widespread across Europe and other continents before successful eradication campaigns eliminated it from most developed nations.

The disease primarily affects domestic cattle of both Bos taurus and Bos indicus species, as well as water buffalo and certain wild bovid species. While CBPP has been eradicated from North America, Europe, and Australia through rigorous control programs, it continues to cause substantial losses in many African countries where it remains a persistent threat to cattle populations. The World Organisation for Animal Health (WOAH, formerly OIE) classifies CBPP as a notifiable disease, requiring immediate reporting to national and international veterinary authorities when detected. This classification reflects the severe economic and trade implications associated with disease outbreaks.

The economic impact of contagious bovine pleuropneumonia extends far beyond direct animal losses. Affected regions face trade restrictions, quarantine costs, surveillance expenses, and the broader economic consequences of reduced cattle productivity. In endemic areas, CBPP contributes to food insecurity and threatens the livelihoods of millions of pastoral and agropastoral communities who depend on cattle for income, nutrition, and social standing. The disease can cause mortality rates ranging from ten to seventy percent in naive populations, with surviving animals often remaining chronically infected and serving as reservoirs for continued transmission within and between herds.

Early detection and rapid response are critical for controlling CBPP outbreaks, as the disease can spread quickly through cattle populations via respiratory aerosols and direct contact between infected and susceptible animals. Treatment options are severely limited, and many countries prohibit antimicrobial therapy for CBPP to prevent the creation of chronic carrier animals that perpetuate transmission. Instead, control strategies focus on vaccination in endemic regions, movement restrictions, surveillance, and stamping-out policies in disease-free areas. Understanding this disease is essential for cattle producers, veterinarians, and animal health authorities working to protect cattle populations and maintain disease-free status in non-endemic regions.

Contagious bovine pleuropneumonia is caused by Mycoplasma mycoides subspecies mycoides small colony type, a unique bacterial pathogen belonging to the class Mollicutes. Unlike conventional bacteria, mycoplasmas lack a rigid cell wall, which makes them naturally resistant to many commonly used antibiotics including penicillins and cephalosporins that target cell wall synthesis. This organism is highly adapted to cattle and has evolved sophisticated mechanisms to evade host immune responses while causing severe inflammatory damage to respiratory tissues. The pathogen is transmitted primarily through inhalation of infectious respiratory droplets expelled by infected cattle during close contact, making crowded housing conditions and communal grazing areas significant risk factors for disease spread.

While there is no genetic predisposition to CBPP infection, certain cattle populations demonstrate varying levels of susceptibility based on their historical exposure to the pathogen. Cattle in regions where CBPP has been endemic for generations may show some degree of resistance compared to completely naive populations encountering the disease for the first time. European cattle breeds introduced to endemic African regions have historically experienced particularly severe outbreaks, likely due to complete lack of prior exposure or selection for resistance. However, all cattle breeds remain susceptible to infection regardless of their geographic origin or breeding background.

Environmental and management factors play crucial roles in CBPP transmission dynamics. The pathogen survives poorly outside the host and is readily inactivated by environmental conditions including sunlight, heat, and desiccation. However, transmission risk increases dramatically when cattle are congregated in close proximity, such as during seasonal migrations, at watering points, in markets, or in communal grazing areas. Drought conditions that force cattle populations to concentrate around limited water and pasture resources have historically precipitated CBPP outbreaks in endemic regions. Similarly, livestock movements associated with trade, transhumance, and restocking following drought or conflict can introduce infection to previously unaffected areas.

Several risk factors increase the likelihood of CBPP introduction and spread within cattle populations. Recent purchase or introduction of new animals without adequate quarantine represents the most significant risk factor for herds in disease-free areas. Age influences disease expression, with adult cattle typically showing more severe clinical signs while young calves may experience milder symptoms but still contribute to transmission. Animals stressed by poor nutrition, concurrent disease, or harsh environmental conditions may be more susceptible to severe disease outcomes. The practice of loaning or sharing bulls between herds, common in many pastoral systems, creates opportunities for disease transmission between otherwise separate cattle populations.

The pathophysiology of CBPP involves complex interactions between the mycoplasma organism and bovine respiratory tissues. Following inhalation, Mycoplasma mycoides colonizes the lower respiratory tract and triggers intense inflammatory responses in the lungs and pleural membranes. The organism produces various toxins and inflammatory mediators that cause direct tissue damage while simultaneously stimulating excessive host immune responses that contribute to pathology. Fibrin accumulation in the pleural space creates the characteristic pleural adhesions and sequestra that define chronic CBPP lesions. Surviving animals may develop encapsulated lung lesions called sequestra that harbor viable organisms for extended periods, allowing them to serve as reservoirs for ongoing transmission within herds.

The clinical presentation of contagious bovine pleuropneumonia varies considerably depending on the stage of infection, the virulence of the strain involved, and the immune status of affected animals. Early warning signs are often subtle and may be easily overlooked, particularly in extensively managed herds where close individual observation is challenging. Initial symptoms typically include mild depression, decreased appetite, and a slight reduction in milk production in dairy animals. Affected cattle may show reluctance to move and tend to lag behind when the herd travels to pasture or water. A soft, intermittent cough may be present in the earliest stages, often becoming more pronounced over several days as the disease progresses.

As CBPP advances, respiratory symptoms become increasingly prominent and form the hallmark clinical presentation of the disease. Affected cattle develop a characteristic stance with the head extended forward and downward, elbows abducted from the body, and back arched in an attempt to ease breathing. Respirations become rapid, shallow, and labored, often accompanied by audible grunting or groaning during expiration. Nasal discharge may progress from clear and serous to thick and mucopurulent as secondary bacterial infections complicate the primary mycoplasma infection. Some animals develop mouth breathing and excessive salivation as respiratory distress intensifies.

Behavioral changes associated with CBPP reflect the discomfort and debilitation caused by progressive respiratory disease. Affected cattle typically separate themselves from the herd, seeking shade and remaining stationary for extended periods. Feed intake decreases dramatically, and animals lose body condition rapidly as the disease progresses. Rumination may cease entirely in severely affected individuals, and water consumption often decreases despite fever. Cattle may stand near water sources but show reluctance to lower their heads to drink due to the discomfort associated with this posture. Social interactions diminish, and previously dominant animals may become passive and withdraw from normal herd dynamics.

Physical examination findings in cattle with CBPP reflect the severe pulmonary and pleural pathology underlying clinical signs. Fever is typically present during the acute phase, with rectal temperatures ranging from 40 to 42 degrees Celsius (104 to 107.6 degrees Fahrenheit). Auscultation of the chest reveals decreased or absent lung sounds over affected areas, often accompanied by friction rubs where inflamed pleural surfaces contact during respiration. Percussion may demonstrate dullness over consolidated lung regions or fluid accumulation in the pleural space. Submandibular and prescapular lymph nodes may be enlarged, and jugular vein distension can occur secondary to impaired cardiac return from extensive pleural effusion.

Disease progression in untreated cases follows a predictable pattern over several weeks to months. Acute cases may succumb within one to three weeks of developing clinical signs, particularly in fully susceptible animals encountering highly virulent strains. Subacute presentations extend over several weeks with fluctuating severity of respiratory signs. Some animals enter a chronic phase characterized by persistent low-grade respiratory compromise, intermittent coughing, and progressive weight loss. These chronically affected animals are particularly concerning from a disease control perspective, as they may appear relatively healthy while harboring sequestered lung lesions containing viable organisms capable of reactivating and initiating new transmission cycles.

Certain clinical presentations constitute emergencies requiring immediate veterinary intervention and notification of animal health authorities. Severe respiratory distress with open-mouth breathing, cyanotic mucous membranes, and collapse indicates critical compromise requiring immediate assessment. Sudden death in multiple animals within a herd, particularly when accompanied by respiratory signs in survivors, strongly suggests CBPP and demands urgent investigation. Any suspected CBPP case in regions officially free of the disease constitutes an emergency requiring immediate reporting to national veterinary services, as early detection and rapid response are essential for preventing establishment and spread. Producers observing these signs should isolate affected animals, restrict all cattle movements, and contact their veterinarian and animal health authorities immediately.

Clinical diagnosis of contagious bovine pleuropneumonia relies on recognition of characteristic respiratory signs combined with knowledge of disease epidemiology and herd history. Veterinarians evaluating cattle with progressive respiratory disease should consider CBPP when animals present with labored breathing, abnormal respiratory posture, pleuritic pain, and fever, particularly in regions where the disease occurs or when recent animal introductions have occurred. Physical examination findings including decreased lung sounds, pleural friction rubs, and thoracic dullness support clinical suspicion. However, clinical signs alone cannot definitively differentiate CBPP from other causes of bovine respiratory disease, necessitating laboratory confirmation for definitive diagnosis.

Laboratory diagnosis of CBPP employs multiple approaches to detect the causative organism or evidence of immune responses to infection. Culture and isolation of Mycoplasma mycoides subspecies mycoides from pleural fluid, lung tissue, or lymph node samples provides definitive confirmation but requires specialized media and expertise available only at reference laboratories. Polymerase chain reaction (PCR) testing offers rapid and sensitive detection of mycoplasma DNA in clinical samples and has become increasingly important for outbreak investigation and surveillance. Serological tests including complement fixation tests (CFT) and competitive enzyme-linked immunosorbent assays (c-ELISA) detect antibodies in serum samples and are widely used for herd screening and certification programs.

Differential diagnosis for CBPP includes numerous other causes of bovine respiratory disease that must be systematically ruled out. Mannheimia haemolytica and Pasteurella multocida cause bacterial pneumonias with somewhat similar presentations, though typically without the characteristic pleural involvement seen in CBPP. Infectious bovine rhinotracheitis (IBR) and bovine viral diarrhea (BVD) cause respiratory disease but often present with additional systemic or upper respiratory signs. Bovine tuberculosis can cause chronic respiratory disease with pulmonary lesions requiring differentiation from CBPP sequestra. Thoracic trauma, heart failure, and neoplastic conditions affecting the thorax may also produce respiratory signs requiring consideration in the diagnostic workup.

Herd-level diagnostics play an essential role in CBPP surveillance, control, and eradication programs. Serological surveys using validated tests allow estimation of herd prevalence and identification of exposed populations. Post-mortem examination of animals dying with respiratory disease or submitted for slaughter provides valuable diagnostic information through identification of characteristic lung and pleural lesions. The pathognomonic marbled appearance of affected lungs, extensive pleural adhesions, and encapsulated sequestra provide strong presumptive evidence of CBPP that can be confirmed through laboratory testing of tissue samples. Systematic surveillance combining clinical observation, serology, and abattoir monitoring forms the foundation of national programs working to maintain or achieve CBPP-free status.

Treatment approaches for contagious bovine pleuropneumonia are complicated by regulatory restrictions, limited therapeutic options, and the broader implications for disease control programs. In many countries officially free of CBPP, treatment of confirmed cases is prohibited by law, with mandatory slaughter and disposal of infected and exposed animals required to prevent disease establishment. These stamping-out policies reflect the severe economic and trade consequences associated with endemic CBPP and the difficulty of achieving eradication once the disease becomes established in cattle populations. Producers must understand and comply with national regulations regarding reportable diseases, as unauthorized treatment attempts may result in legal penalties and undermine broader disease control efforts.

In regions where CBPP is endemic and treatment is permitted, antimicrobial therapy may reduce clinical severity and mortality in individual animals but has significant limitations. Mycoplasma mycoides subspecies mycoides lacks a cell wall and is therefore inherently resistant to beta-lactam antibiotics including penicillins and cephalosporins. Potentially effective antimicrobials include tetracyclines, macrolides, and fluoroquinolones, though in vivo efficacy is variable and complete elimination of the organism is rarely achieved. Tylosin, oxytetracycline, and florfenicol have been used with varying success, but treated animals frequently remain chronically infected and capable of transmitting disease even after apparent clinical recovery. This phenomenon underlies the prohibition on treatment in many disease control programs.

Supportive care measures may improve comfort and survival in valuable animals where treatment is permitted and economically justified. Provision of palatable feed and fresh water encourages continued intake in animals with reduced appetite. Protection from environmental stressors including extreme temperatures, precipitation, and wind reduces metabolic demands on compromised animals. Non-steroidal anti-inflammatory drugs may provide symptomatic relief from fever and pleuritic pain, though withdrawal periods must be strictly observed in food-producing animals. Severely affected animals may benefit from reduced activity and separation from the main herd to minimize respiratory demands and stress.

Surgical intervention plays no routine role in CBPP management, though thoracocentesis (chest tap) may provide temporary relief in animals with substantial pleural effusion causing respiratory compromise. This procedure removes accumulated fluid from the pleural space, allowing greater lung expansion and improved breathing. However, fluid typically reaccumulates, and the procedure addresses only symptoms without affecting the underlying disease process. Surgical removal of encapsulated lung sequestra has been attempted experimentally but is not practical for field application and does not prevent continued transmission from treated animals.

Herd treatment protocols in endemic regions focus on reducing transmission and clinical disease impact while maintaining economically viable production. Mass antimicrobial treatment of exposed but clinically normal animals has been attempted with varying success during outbreak situations. However, this approach raises concerns about antimicrobial resistance development and may simply suppress clinical signs while allowing continued subclinical infection and transmission. Strategic timing of treatments during high-risk periods, combined with vaccination and movement management, forms part of integrated control programs in some endemic regions.

Treatment decisions must carefully weigh multiple factors including individual animal value, regulatory requirements, disease control implications, and economic realities. In endemic regions with limited resources, treatment costs may exceed the value of affected animals, particularly when chronic infection and reduced productivity are likely outcomes. The public health implications of antimicrobial use in food animals, including withdrawal period compliance and resistance concerns, require consideration. For most situations outside endemic regions, the appropriate response to confirmed or strongly suspected CBPP involves immediate notification of veterinary authorities, isolation of affected and contact animals, movement restrictions, and cooperation with official disease response programs rather than attempted treatment.

Recovery from contagious bovine pleuropneumonia depends on disease severity, timing of intervention, host immune response, and whether treatment was administered. Animals surviving acute CBPP episodes typically require extended convalescence periods ranging from several weeks to several months before returning to normal function. During this recovery period, animals often remain underweight, show reduced exercise tolerance, and may experience intermittent respiratory symptoms reflecting residual pulmonary damage. Full recovery of pre-illness body condition and productivity may take six months or longer, and some animals never completely return to baseline performance levels due to permanent lung scarring and reduced respiratory capacity.

Post-treatment care and monitoring requirements reflect the complex nature of CBPP and its control. Animals recovering from clinical disease require ongoing observation for signs of relapse or disease progression. Regular assessment of body condition, respiratory rate and effort, appetite, and milk production (in dairy animals) helps identify animals failing to recover appropriately. Temperature monitoring during the recovery period can detect fever spikes suggesting persistent or reactivating infection. Any deterioration in recovering animals warrants veterinary evaluation and reconsideration of prognosis. In regions where CBPP eradication is the goal, recovered animals are typically not retained due to their potential to remain chronic carriers.

Prognostic factors influencing CBPP outcomes include disease severity at presentation, extent of lung involvement, presence of complications, and age and overall health status of affected animals. Animals presenting with mild to moderate disease before extensive lung consolidation develops generally have more favorable prognosis than those with severe respiratory compromise and massive pleural effusion. Young calves often experience milder clinical disease than adults but may develop chronic infections that persist into maturity. Pre-existing health conditions, concurrent infections, and nutritional status all influence recovery potential. Animals with sequestered lung lesions visible on imaging studies carry guarded long-term prognosis regardless of apparent clinical recovery.

Return to production considerations vary depending on the production context and regulatory environment. In endemic regions where CBPP-recovered animals may be retained, producers should expect prolonged periods of reduced productivity before animals approach pre-illness performance. Dairy cattle may never return to peak milk production following significant pulmonary damage. Breeding animals may experience reduced fertility during and following recovery periods due to general debilitation and stress. Most importantly, recovered animals frequently remain chronically infected and capable of transmitting CBPP to susceptible herdmates, making their retention a continued disease risk. In regions pursuing CBPP eradication, recovered animals are typically culled regardless of individual animal value to protect broader cattle populations and trade status.

Vaccination represents the primary tool for CBPP prevention in endemic regions where the disease cannot be eliminated through stamping-out approaches alone. Live attenuated vaccines based on the T1/44 strain have been used for decades throughout Africa and provide partial protection against clinical disease and mortality. Vaccination does not prevent infection entirely but reduces disease severity, mortality rates, and shedding of organisms by infected animals. Current vaccines require annual administration and have limitations including variable efficacy, relatively short duration of immunity, and potential to cause adverse reactions at injection sites. Ongoing research aims to develop improved vaccines with enhanced efficacy and safety profiles.

Biosecurity measures form the cornerstone of CBPP prevention in disease-free regions and complement vaccination programs in endemic areas. Preventing introduction of infected animals through rigorous pre-movement testing and certification provides the first line of defense for uninfected herds. Quarantine periods for newly acquired animals allow observation for disease development and prevent direct contact with existing herd members during the highest risk period. Physical separation from neighboring cattle populations, maintenance of boundary fences, and prevention of contact at shared water sources or grazing areas reduce transmission opportunities. Markets and congregation points represent high-risk environments where strict hygiene and segregation practices can reduce disease spread.

Nutritional management contributes to CBPP prevention by maintaining immune competence and overall animal health. Well-nourished cattle mount more effective immune responses to vaccination and may experience milder disease if infected. Ensuring adequate protein, energy, and micronutrient intake supports respiratory tract defenses and general disease resistance. Avoiding nutritional stresses that compromise immunity, particularly during high-risk periods such as drought or late gestation, helps maintain herd resilience against infectious disease challenges. Mineral supplementation appropriate to local soil and forage conditions addresses deficiencies that might otherwise impair immune function.

Management practices supporting CBPP prevention extend beyond individual animal care to encompass broader herd and production system considerations. Maintaining closed herds with minimal outside animal introductions dramatically reduces disease introduction risk. When animal purchases are necessary, sourcing from certified disease-free herds or regions provides additional assurance. Avoiding sharing of equipment, personnel, or resources with herds of unknown health status prevents indirect transmission. Training farm workers to recognize early disease signs enables rapid detection and response when prevention measures fail. Developing relationships with veterinary services ensures access to expertise and diagnostic capabilities when needed.

Quarantine and testing protocols provide systematic approaches to managing disease introduction risk. Standard quarantine periods of at least thirty days allow detection of clinical disease in recently infected animals before herd mixing. Serological testing during or following quarantine identifies animals with evidence of exposure that might otherwise appear healthy. Testing protocols for breeding animals, particularly bulls used across multiple herds, prevent dissemination of infection through breeding programs. National and regional surveillance programs incorporating serological surveys, abattoir monitoring, and clinical reporting provide early warning of disease activity and support maintenance of disease-free status. Compliance with official testing and certification requirements facilitates trade while protecting cattle populations from CBPP introduction.

Daily management and monitoring practices for cattle in CBPP-endemic regions or herds recovering from outbreaks require heightened awareness and systematic observation. Handlers should assess respiratory status of all cattle daily, noting any animals showing increased respiratory rate, coughing, nasal discharge, or reluctance to move with the herd. Feed intake monitoring, whether through direct observation or assessment of residual feed in troughs, provides early indication of animals going off feed before other clinical signs become apparent. Maintaining consistent daily routines reduces stress that might exacerbate disease in subclinically infected animals while facilitating detection of behavioral changes indicating illness. Documentation of individual animal observations enables tracking of disease progression and response to interventions.

Housing and environmental management significantly influence CBPP transmission risk and disease outcomes. In intensive or semi-intensive systems, adequate ventilation reduces respiratory pathogen concentration in shared airspaces and decreases transmission probability. Stocking densities should allow reasonable spacing between animals to minimize close contact transmission. Quarantine facilities capable of housing isolated animals separately from the main herd prove essential for managing suspect cases and new arrivals. Protection from environmental extremes reduces physiological stress that might compromise immune function or exacerbate respiratory disease. Clean, dry bedding and well-drained housing areas support overall health and comfort.

Integrated herd health programs provide systematic frameworks for CBPP prevention and control within broader animal health management. Regular veterinary consultations ensure access to expertise for disease recognition, diagnostic sampling, and treatment decisions where permitted. Vaccination scheduling aligned with local disease risk and seasonal patterns optimizes protection while minimizing vaccine reactions. Coordination with animal health authorities facilitates surveillance activities and ensures compliance with regulatory requirements. Integration of CBPP prevention with management of other significant diseases creates efficient approaches to overall herd health rather than addressing conditions in isolation.

Record keeping and monitoring systems support effective CBPP management by documenting herd health status, interventions, and outcomes over time. Individual animal identification enables tracking of vaccination history, disease events, and test results throughout each animal's productive life. Herd-level records of disease incidence, mortality, and veterinary interventions reveal trends requiring attention and demonstrate compliance with official requirements. Movement records documenting animal origins, destinations, and timing prove essential for traceback investigations if disease occurs. Production records including milk yield, weight gains, and reproductive performance provide indirect indicators of herd health status and treatment efficacy.

Economic considerations fundamentally influence CBPP management decisions at individual animal and herd levels. Prevention investments including vaccination, biosecurity infrastructure, and testing programs must be weighed against disease risk and potential losses. Treatment costs, where permitted, require comparison with expected outcomes and alternative approaches including culling. The value of individual animals influences decisions about intervention intensity, while broader economic factors including market access and trade certification requirements shape overall management strategies. In endemic regions, balancing disease control investments against other production constraints challenges producers with limited resources. Understanding the full economic impact of CBPP, including production losses, treatment costs, and trade implications, supports informed decision-making that protects both animal welfare and producer livelihoods.

All cattle breeds are susceptible to contagious bovine pleuropneumonia, as the disease reflects infection with a specific bacterial pathogen rather than inherited genetic susceptibility. However, historical observations suggest that European Bos taurus breeds may experience more severe clinical disease when introduced to endemic regions compared to indigenous African cattle populations that have coexisted with CBPP for many generations. This apparent difference likely reflects immune selection in populations historically exposed to the disease rather than true genetic resistance. Zebu cattle (Bos indicus) common throughout tropical regions demonstrate similar susceptibility to CBPP, with disease severity influenced more by immune history than breed genetics.

Production type considerations influence CBPP impact and management priorities across different cattle enterprises. Dairy cattle concentrated in intensive housing systems face elevated transmission risk from close contact but may benefit from more frequent observation enabling early disease detection. High-producing dairy breeds may experience more severe production impacts from respiratory disease due to elevated metabolic demands. Beef cattle in extensive grazing systems face different risk patterns associated with congregation at water points, markets, and seasonal grazing areas. Breeding herds face particular concerns about transmission through natural service when bulls are shared between farms or move between cow groups.

Genetic selection and testing opportunities for CBPP resistance remain limited compared to some other livestock diseases. While variation in disease outcomes between animals suggests some genetic component to host responses, no validated genetic markers or breeding values for CBPP resistance currently exist. Research into host genetic factors influencing mycoplasma infections continues but has not yet yielded practical selection tools. Current genetic management focuses on maintaining overall robust health and immune function rather than specific CBPP resistance. The most effective genetic strategy for most producers remains avoiding disease introduction altogether rather than attempting to breed for resistance to a pathogen their cattle should never encounter.

Contagious bovine pleuropneumonia commonly occurs alongside other respiratory pathogens that may complicate diagnosis and worsen clinical outcomes. Secondary bacterial pneumonias caused by Mannheimia haemolytica, Pasteurella multocida, or Histophilus somni frequently develop when CBPP damages respiratory tract defenses, creating more severe clinical presentations than either infection alone. Concurrent bovine respiratory syncytial virus (BRSV) or parainfluenza-3 (PI3) viral infections may predispose cattle to more severe CBPP or complicate recovery. Animals with compromised immunity from concurrent bovine viral diarrhea virus (BVDV) infection may experience particularly severe CBPP outcomes. Managing these co-infections requires comprehensive diagnostic evaluation and treatment approaches addressing multiple pathogens.

Several conditions produce respiratory signs similar to CBPP and must be considered in differential diagnosis. Tuberculosis causes chronic respiratory disease with lung lesions that may superficially resemble CBPP sequestra, requiring laboratory differentiation. Other mycoplasma species including Mycoplasma bovis cause respiratory disease in cattle but typically present differently and affect different age groups primarily. Aspiration pneumonia following improper oral medication administration may mimic infectious pneumonia clinically. Traumatic reticuloperitonitis with thoracic involvement can produce pleurisy and respiratory compromise resembling CBPP. Careful clinical evaluation combined with appropriate diagnostic testing distinguishes these conditions from true CBPP.

Complications and sequelae of CBPP extend beyond the acute respiratory phase and influence long-term animal health and productivity. Chronic respiratory insufficiency from permanent lung damage limits exercise tolerance and productivity in surviving animals. Fibrous pleural adhesions may restrict lung expansion and predispose to recurrent respiratory problems. Encapsulated lung sequestra containing viable Mycoplasma mycoides pose ongoing transmission risks and may reactivate causing clinical relapse. Secondary joint infections (arthritis) occasionally occur as a complication of systemic mycoplasma spread. Weight loss and poor body condition during prolonged illness may have lasting effects on reproductive performance and productive capacity even after apparent clinical recovery.